Clinical Trials Logo

BK Virus Infection clinical trials

View clinical trials related to BK Virus Infection.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04693637 Completed - Clinical trials for Cytomegalovirus Infections

Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Prevent
Start date: January 15, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 2 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus.

NCT ID: NCT04605484 Completed - BK Virus Infection Clinical Trials

Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia

Start date: March 22, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare Posoleucel (formerly known as ALVR105; Viralym-M) to placebo in kidney transplant recipients who have high or low levels of BK virus in their blood.

NCT ID: NCT04294472 Completed - BK Virus Infection Clinical Trials

A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients

Start date: August 5, 2020
Phase: Phase 2
Study type: Interventional

This clinical research study will test the safety and efficacy of the investigational medication MAU868, compared to a placebo, in patients who have had a kidney transplant who have active BK virus.

NCT ID: NCT03532971 Completed - BK Virus Infection Clinical Trials

Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes

Start date: July 30, 2018
Phase:
Study type: Observational

This research study is evaluating the reactivation of BK virus in patients who have undergone allogeneic hematopoietic-cell transplantation.

NCT ID: NCT01789203 Completed - BK Virus Infection Clinical Trials

Ciprofloxacin for Prevention of BK Infection

Start date: January 2013
Phase: Phase 4
Study type: Interventional

BK infection is an important cause of graft dysfunction and graft loss after renal transplantation. It has been widely accepted that emergence of BK virus correlates with the more potent immunosuppressive agents used to lower acute rejection rates. In contrast to other opportunistic infections after transplantation, for which routine prophylactic agents are administered, there is no effective agent for the prevention of BK infection. Some data, however, suggests that quinolone antibiotics such as ciprofloxacin may have activity against BK virus. This has led us to investigate whether routine, short-term ciprofloxacin administration post-transplant can lower the incidence of BK infection.

NCT ID: NCT01624948 Completed - BK Virus Infection Clinical Trials

Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients

Start date: September 2012
Phase: Phase 4
Study type: Interventional

This study is examining the safety and efficacy of converting anti-rejection therapy from mycophenolic acid (MPA) to Zortress (everolimus) in renal transplant recipients with BK virus infection. The study will also determine if immune monitoring tests can detect an association between BK virus infection and transplant rejection episodes, based on the specific BKV infection treatment regimen. The investigators hypothesize that an anti-rejection regimen with Zortress (everolimus) and tacrolimus + prednisone will be superior to a standard regimen of reduced dose MPA and tacrolimus + prednisone in patients who have undergone renal transplantation and have active BKV infections.